KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin: 2013-2024

Historic Gross Margin for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Dec 2024 value amounting to 88.23%.

  • Supernus Pharmaceuticals' Gross Margin rose 14.00% to 90.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.61%, marking a year-over-year decrease of 44.00%. This contributed to the annual value of 88.23% for FY2024, which is 202.00% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Gross Margin of 88.23% as of FY2024, which was up 2.34% from 86.21% recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Gross Margin registered a high of 89.92% during FY2020, and its lowest value of 86.21% during FY2023.
  • Its 3-year average for Gross Margin is 87.12%, with a median of 86.93% in 2022.
  • Its Gross Margin has fluctuated over the past 5 years, first slumped by 584bps in 2020, then spiked by 202bps in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Gross Margin stood at 89.92% in 2020, then crashed by 287bps to 87.05% in 2021, then declined by 13bps to 86.93% in 2022, then tumbled by 72bps to 86.21% in 2023, then spiked by 202bps to 88.23% in 2024.